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Background: 11C-PiB has been developed as a positron-emission tomography (PET) ligand for evaluating fibrillar β-
amyloid (Aβ) in the human brain. The ligand is rapidly metabolized, with approximately 10% of intact tracer
remaining 30 min after injection. When 11C-PiB is used as a treatment endpoint in intervention studies for
Alzheimer’s disease (AD), a concern is whether the clearance of the tracer changes from one scan to the next,
increasing within subject variability in the PET signal. Subjects enrolled in AD trials may start or stop medications
that inhibit or induce xenobiotic metabolizing enzymes such as the cytochrome P450 (CYP) isozymes.
Findings: We conducted CYP phenotyping in recombinantly expressed systems, and in human liver microsomes, to
evaluate CYP isozyme contributions to the metabolism of PiB (carrier) and profiled microsomal and hepatocyte
incubations for metabolites. The metabolism of PiB appears to be polyzymic, with direct conjugation via UDP-
glucuronosyltransferases (UGTs) also occurring.
Conclusion: It is unlikely that CYP inhibition or induction will significantly influence the clearance of 11C-PiB.
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Background
The thioflavin T derivative, N-methyl-[11C]2-(40methyla-
minophenyl)-6 hydroxybenzothiazole (11C-PiB), has been
developed as a positron-emission tomography (PET)
ligand for evaluating fibrillar β-amyloid (Aβ) in the
human brain. Retention of 11C-PiB in the cortex corre-
lates with the distribution of insoluble deposits of Aβ [1]
and has been investigated extensively as a biomarker for
Alzheimer’s disease (AD) [2] and used as an endpoint in
interventional trials [3,4]. 11C-PiB is rapidly cleared from
the blood, with approximately 10% of intact tracer
remaining 30 min after injection [5]. Test-retest studies
conducted hours to weeks apart have reported interscan
differences of less than 10% [6]. These test-retest esti-
mates may not predict the variability in measurement
over longer periods of time, such as months to years.* Correspondence: mschmid4@its.jnj.com
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reproduction in any medium, provided the origA critical issue is the possible changes in clearance of
the tracer as this could alter the input function into the
brain. Metabolism of a tracer that depends primarily on
one of the cytochrome P450 (CYP) isoenzymes could be
vulnerable to inhibition by particular medications. Sub-
jects enrolled in AD trials may start or stop a number of
medications that inhibit or induce CYP enzymes such as
statins, well-known potent inhibitors of the CYP3A iso-
enzymes, or experience conditions that could affect CYP
expression [7]. The metabolism of the serotonin 5HT1A
receptor PET ligand FCWAY is significantly reduced by
pretreatment with disulfuram, a potent inhibitor of
CYP2E1. The ratio of specific distribution volume of
tracer in target rich to target poor regions increased
twofold after pretreatment with disulfuram [8]. Such a
change would confound measurement of change in PiB
signal as an indicator of disease progression and poten-
tially obscure detection of treatment effects using PiB as
an endpoint. Current practice in acquiring PiB PET
scans does not include any blood sampling, so changes
in tracer clearance from one scan to the next would not
be detected. We wished to determine the metabolicis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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of 11C-PiB could be susceptible to CYP inhibition or in-
duction - specifically, whether the metabolism of PiB via
the most abundant CYPs is mono- or polyzymic, and
whether direct conjugation of PiB is a significant clear-
ance pathway. While these in vitro systems are necessar-
ily reductionist in comparison with the in vivo systems,
they are generally agreed to provide valuable insight into
likely in vivo outcomes.
Materials and methods
Cryopreserved human (male and female), male Beagle
dog, male Sprague–Dawley rat, and male Swiss mouse
hepatocytes were purchased from In Vitro Technologies
(In Vitro Technologies, Baltimore, MD, USA). Sulfaphena-
zole and quinidine were purchased from Sigma (St. Louis,
MO, USA). Alpha-naphthoflavone was purchased from
Merck KGaA (Darmstadt, Germany). Benzylphenobarbital
and ketoconazole were synthesized in-house. PiB was
purchased from ABX GmbH (Radeberg, Germany). Diag-
nostic P450 inhibitors and test compounds were suppliedFigure 1 Percentage of PiB remaining after incubation in HLM and re
15 (dark gray) and 60 min (light gray) incubations at 1 μM substrate conce
contributions to turnover of PiB based on unscaled rhCYP data. (C) Relative
abundances of CYPs in human liver, according to Rodrigues [10].as dry powder and dissolved in 100% dimethylsulfoxide
(DMSO). All other materials were of analytical or higher
grade and used without further purification. Cytochrome
P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4 were
obtained as singly expressed enzymes (Baculovirus trans-
fected insect cell system, rhCYPs) from BD Gentest
(Woburn, MA, USA). Human liver microsomes (HLM)
were obtained from BD Gentest (Woburn, MA, USA) as a
pool from 50 donors, lot 01220.
Incubations with recombinantly expressed cytochrome
P450s
The assay mixtures (final incubation volume of 125 μL) in
0.255 M phosphate buffer with 0.575% (w/v) KCl (pH 7.4)
contained PiB (1.0 μM), 2.0 mM nicotinamide-adenine
dinucleotide phosphate (reduced form) (NADPH), and a
recombinantly expressed cytochrome P450 enzyme prep-
aration at 100 pmol/mL. After a 10 min preincubation at
37C, the reaction was initiated by addition of 2.0 mM
NADPH and incubated for 15 and 60 min. The reactions
were terminated by the addition of two volumes oflative contributions to turnover. (A) % PiB remaining after 0 (black),
ntration with rhCYPs 1A2, 2C9, 2C19, 2D6, and 3A4. (B) Relative
contributions to turnover of PiB after scaling for the relative
Figure 2 Percentage of PiB remaining after 60 min incubations in HLM. Percentage of PiB remaining after 0 min (black) and 60 min
(dark gray) incubations in HLM at 1 μM substrate concentration with no inhibition (two rightmost bars), or in the presence of CYP-specific
chemical inhibitors.
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rpm for 10 min. From the resulting supernatant, 10 µL
was analysed by liquid chromatography/tandem mass
spectrometry (LC-MS/MS). Control experiments were
performed by substituting the active enzyme preparation
by insect cell preparations containing no rhCYP.
Human liver microsomal metabolism in the absence and
presence of cytochrome P450 diagnostic inhibitors
Assay mixtures (final incubation volume of 125 μL) in
0.255 M phosphate buffer with 0.575% (w/v) KCl (pH 7.4)
contained PiB (1.0 μM), an NADPH regenerating system
(consisting of 1.65 mM glucose-6-phosphate, 0.125 U
glucose-6-phosphate dehydrogenase, 0.1 mM NADP, and
5.0 mM magnesium chloride), 1.0 mg/mL of pooled
human liver microsomes, and alpha-naphthoflavone
(3 μM), sulfaphenazole (10 μM), benzylphenobarbital



















Figure 3 Metabolites identified in incubations with human liver microinhibitors of cytochromes P450 1A2, 2C9, 2C19, 2D6, and
3A4, respectively. After a 10 min preincubation at 37C,
the reaction was initiated by addition of 0.15 mM NADP
and further incubated for either 15 or 60 min. The reac-
tions were terminated by the addition of two volumes
DMSO. Samples were subsequently centrifuged at 4,000
rpm for 10 min. From the resulting supernatant, 10 μL
was analyzed by LC-MS/MS.
Hepatocyte incubations
PiB was incubated in 24-well plates at a final concentra-
tion of 1.0 μM for 0, 15, and 60 min, with hepatocyte cell
cultures (1 million viable cells/mL), after which the incu-
bations were quenched with two volumes of acetonitrile.
LC-MS/MS detection
Quantification was performed on a TSQ-Vantage instru-
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age was set to 78 V, and the intensity of two transitions
(257 > 242 at a collision energy (CE) = 27 V; 257 > 215,
CE = 36 V) were measured during the experiment.
Elution was performed on a Waters XBridge C18 column
(3 × 2.1 mm, 2.5 μm; Waters, Boston MA, USA). Solvents
A (0.1% formic acid in water) and B (0.1% formic acid in
acetonitrile) were used at a flow rate of 500 μL/min. The
gradient employed was solvent A 95% as the start condi-
tion followed by a linear ramp of organic phase concentra-
tion from 5% B to 95% B over 1.3 min. The final ratio was
held for a further 0.6 min and then reduced again to 5% B
over 0.05 min. Data was processed using QuickQuan
(Thermofisher Scientific, Bremen, Germany).
Qualitative high resolution LC/MS data was acquired
on a Waters Premier hybrid quadrupole time-of-flight
(QToF) mass spectrometer (Waters, Boston MA, USA)
equipped with a liquid chromatography system, using a
10 min gradient method and an Acquity UPLC BEH
C18 (2.1 × 100 mm, 1.7 μm) column (Waters, Boston
MA). The QToF Premier operated with a cone voltage
of 30 eV and collision energy of 30 eV. The gradient
employed was 95% solvent A (25 mM ammonium acet-
ate, pH = 9) as the start condition followed by a linear
ramp of organic phase concentration from 5% B (25 mM
ammonium acetate/MeOH/acetonitrile 10/10/80) toFigure 4 Peak areas observed for the desmethyl metabolite. (A) RhCY
chemical inhibitors.95% B over 6.5 min. The final ratio was held for 2 min
and then reduced again to 5% B over 1 min. Interpret-
ation of data was performed with Metabolynx software
(Waters, Boston, MA, USA) [9].
Results
Based on the observed turnovers, PiB is a substrate for all
five of the major human CYPs, with rhCYP1A2 dominat-
ing. Each incubation only contains a single CYP at an
effective abundance of 100%. Scaling for the approximate
relative abundances of the major five CYP isoforms in
human liver [10] indicates that PiB is likely to be primarily
metabolized by CYPs 3A4, 1A2, and 2C9, with only minor
contributions from 2C19 and 2D6 (Figure 1A,B).
The turnover of PiB in human liver microsomes was
approximately 35% after 60 min. A significant reduction
in turnover was observed with inhibitors of CYPs 1A2
and 3A4, and a reduction in turnover is also apparent
for CYPs 2C19, 2C9, and 2D6 (Figure 2).
The HLM incubations from the phenotyping experi-
ments and the separate incubations performed with
human, rat, dog, and mouse hepatocytes were profiled
for PiB metabolites. The only drug-related species
detected in HLM was the desmethyl metabolite. Add-
itionally present in human hepatocyte incubations were
two glucuronide conjugates, assumed to be formed byP incubations. (B) Incubations with HLM in the presence or absence of
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and of the secondary amine. A combination demethyla-
tion/glucuronidation metabolite was also detected, but it
was not possible to assign the glucuronidation site for
this metabolite (Figure 3).
In rhCYP incubations, the desmethyl metabolite was
the only drug-related species observed. Despite high
turnover with 1A2 (and 3A4), only low levels of the des-
methyl metabolite were present. In the HLM incubations
with inhibitors of 1A2 and 3A4, concentrations of the
desmethyl metabolite increased over time, while with
2C19, 2C9, and 2D6, concentrations were reduced at 60
min compared with 15 min (Figure 4). These data are
together consistent with a two-step pathway in which all
isoforms are able to demethylate, but 1A2 and 3A4 can
then metabolize the desmethyl metabolite to a secondary
product not detectable within the limits of detection of
the qualitative LC/MS method used.Discussion
The results of experiments using in vitro human systems
indicate that PiB is metabolized via both oxidative and
conjugative mechanisms. The dominant routes of me-
tabolism are N-demethylation and glucuronidation. The
metabolism of PiB appears to be polyzymic, with at least
two of the major human CYPs (1A2 and 3A4), contrib-
uting to metabolism, together with UDP-glucuronosyl-
transferase (UGT) involvement.
These results assume that the principal pathways
observed in these in vitro human metabolizing systems
translate to in vivo. In vivo drug metabolism is typically
found to be more, not less complex than that observed
in vitro and one metabolite known to be formed in man,
a sulfate conjugate [11], was not observed in these
experiments. Moreover, the absolute contributions of
oxidation and conjugation to clearance cannot be mea-
sured without authentic standards. A fuller understand-
ing of the enzyme kinetics involved in biotransformation
of PiB would afford improved predictions of its in vivo
pharmacokinetics and susceptibility to drug-drug interac-
tions. Even so, the multiple pathways determined here to
be involved in the metabolic clearance of PiB reduce the
likelihood that drug-drug interactions are a source of vari-
ability in quantitative measurement of 11C-PiB PET.Competing interests
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